Literature DB >> 34362811

The RALES Legacy and Finerenone Use on CKD Patients.

José A Moura-Neto1, Claudio Ronco2.   

Abstract

Entities:  

Keywords:  aldosterone; chronic kidney disease; chronic kidney failure; randomized controlled trials

Mesh：

Substances：

Year:  2021        PMID： 34362811      PMCID： PMC8729570          DOI： 10.2215/CJN.02150221

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   10.614


× No keyword cloud information.
  11 in total

1.  Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals With Renal Impairment.

Authors:  Roland Heinig; Nina Kimmeskamp-Kirschbaum; Atef Halabi; Silvia Lentini
Journal:  Clin Pharmacol Drug Dev       Date:  2016-07-18

2.  Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes.

Authors:  José A Moura-Neto; Claudio Ronco
Journal:  N Engl J Med       Date:  2021-03-18       Impact factor: 91.245

3.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

4.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Authors:  Vlado Perkovic; Meg J Jardine; Bruce Neal; Severine Bompoint; Hiddo J L Heerspink; David M Charytan; Robert Edwards; Rajiv Agarwal; George Bakris; Scott Bull; Christopher P Cannon; George Capuano; Pei-Ling Chu; Dick de Zeeuw; Tom Greene; Adeera Levin; Carol Pollock; David C Wheeler; Yshai Yavin; Hong Zhang; Bernard Zinman; Gary Meininger; Barry M Brenner; Kenneth W Mahaffey
Journal:  N Engl J Med       Date:  2019-04-14       Impact factor: 91.245

5.  Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Authors:  Hiddo J L Heerspink; Hans-Henrik Parving; Dennis L Andress; George Bakris; Ricardo Correa-Rotter; Fan-Fan Hou; Dalane W Kitzman; Donald Kohan; Hirofumi Makino; John J V McMurray; Joel Z Melnick; Michael G Miller; Pablo E Pergola; Vlado Perkovic; Sheldon Tobe; Tingting Yi; Melissa Wigderson; Dick de Zeeuw
Journal:  Lancet       Date:  2019-04-14       Impact factor: 79.321

Review 6.  Chronic Hyperkalemia in Cardiorenal Patients: Risk Factors, Diagnosis, and New Treatment Options.

Authors:  Luca Di Lullo; Claudio Ronco; Antonio Granata; Ernesto Paoletti; Vincenzo Barbera; Mario Cozzolino; Maura Ravera; Maria Fusaro; Antonio Bellasi
Journal:  Cardiorenal Med       Date:  2018-10-25       Impact factor: 2.041

7.  Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

Authors:  David N Juurlink; Muhammad M Mamdani; Douglas S Lee; Alexander Kopp; Peter C Austin; Andreas Laupacis; Donald A Redelmeier
Journal:  N Engl J Med       Date:  2004-08-05       Impact factor: 91.245

Review 8.  Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?

Authors:  Hermann Haller; Anna Bertram; Klaus Stahl; Jan Menne
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

9.  Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.

Authors:  George L Bakris; Rajiv Agarwal; Stefan D Anker; Bertram Pitt; Luis M Ruilope; Peter Rossing; Peter Kolkhof; Christina Nowack; Patrick Schloemer; Amer Joseph; Gerasimos Filippatos
Journal:  N Engl J Med       Date:  2020-10-23       Impact factor: 91.245

Review 10.  Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review.

Authors:  Gloria Cordoba; Lisa Schwartz; Steven Woloshin; Harold Bae; Peter C Gøtzsche
Journal:  BMJ       Date:  2010-08-18
View more
  3 in total

1.  Hyperkalemia with Mineralocorticoid Receptor Antagonist Use in People with CKD: Understanding and Mitigating the Risks.

Authors:  Murray Epstein; Roberto Pecoits-Filho; Catherine M Clase; Manish M Sood; Csaba P Kovesdy
Journal:  Clin J Am Soc Nephrol       Date:  2021-12-01       Impact factor: 8.237

Review 2.  Mineralocorticoid receptor antagonists for cardioprotection in chronic kidney disease: a step into the future.

Authors:  Maria-Eleni Alexandrou; Marieta P Theodorakopoulou; Mehmet Kanbay; Pantelis A Sarafidis
Journal:  J Hum Hypertens       Date:  2022-01-04       Impact factor: 2.877

Review 3.  Efficacy and Safety of Finerenone in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Authors:  Ming-Zhu Zhang; Wujisiguleng Bao; Qi-Yan Zheng; Ya-Hui Wang; Lu-Ying Sun
Journal:  Front Pharmacol       Date:  2022-02-07       Impact factor: 5.810
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.